ALPS ‐ HCC Score: A Dynamic Liver Stiffness Measurement‐Based Machine Learning Model to Predict Risk of Hepatocellular Carcinoma
- 14 September 2026
- journal article
- research article
- Published by Wiley in Liver International
- Vol. 46 (10) , e70866
Abstract
Background & Aims: Existing hepatocellular carcinoma (HCC) risk scores specific to chronic hepatitis B (CHB) mostly rely solely on baseline indicators, limiting their applicability in clinical practice. By incorporating dynamic and static indicators, this study aimed to address this limitation by developing a machine learning (ML) model for HCC prediction in patients with CHB and compensated advanced chronic liver disease (cACLD). Methods: ML models were trained to predict HCC in 1 272 patients with CHB and cACLD, who underwent at least 2 measurements from different centres and were further tested with external cohorts ( n = 601). The first and last liver stiffness measurements were defined as the baseline and follow‐up values, respectively. Results: A total of 1 873 individuals with CHB and cACLD were included, with 192 patients (10.3%) developing HCC after a median of 30.7 months. Based on LASSO logistic regression, baseline age, baseline albumin concentration, follow‐up albumin concentration, follow‐up platelet count, and change in the liver stiffness measurement (∆LSM) were selected, with ∆LSM identified as the most important indicator. Developed using XGBoost, the ALPS‐HCC score achieved the highest integrated AUROC (0.852), Harrell's C‐index (0.852), and F1 score (0.944), and performed significantly better than existing HCC risk scores. Based on these results, our risk stratification performed well in terms of prognosis in the validation cohort, including the identification of low‐risk ( n = 250; reference), intermediate‐risk ( n = 91; hazard ratio [HR] = 5.25), and high‐risk ( n = 41; HR = 24.47) groups. Conclusions: ALPS‐HCC score provides robust predictive power and screening capability for predicting HCC risk in patients with CHB and cACLD.Keywords
Funding Information
- Science Fund for Distinguished Young Scholars of Guangdong Province (2022B1515020024)
- National Key Research and Development Program of China (2023YFC2507500)
- National Natural Science Foundation of China (82070574)
- National Natural Science Foundation of China (82203395)
This publication has 32 references indexed in Scilit:
- Liver stiffness measurement trajectory analysis for prognosis in patients with chronic hepatitis B and compensated advanced chronic liver diseaseAnnals of Hepatology, 2025
- A Liver Stiffness–Based Etiology-Independent Machine Learning Algorithm to Predict Hepatocellular CarcinomaClinical Gastroenterology and Hepatology, 2023
- Change in serial liver stiffness measurement by magnetic resonance elastography and outcomes in NAFLDHepatology, 2022
- Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver DiseaseClinical Gastroenterology and Hepatology, 2021
- Toronto HCC risk index: A validated scoring system to predict 10-year risk of HCC in patients with cirrhosisJournal of Hepatology, 2018
- PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapyJournal of Hepatology, 2016
- Expanding consensus in portal hypertensionJournal of Hepatology, 2015
- EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosisJournal of Hepatology, 2015
- Determination of reliability criteria for liver stiffness evaluation by transient elastographyHepatology, 2012
- Risk Assessment of Hepatitis B Virus–Related Hepatocellular Carcinoma Development Using Liver Stiffness Measurement (FibroScan) σHepatology, 2010